4.5 Article

Early-Onset Bipolar Disorder and Treatment Delay Are Risk Factors for Poor Outcome in Adulthood

Journal

JOURNAL OF CLINICAL PSYCHIATRY
Volume 71, Issue 7, Pages 864-872

Publisher

PHYSICIANS POSTGRADUATE PRESS
DOI: 10.4088/JCP.08m04994yel

Keywords

-

Funding

  1. AstraZeneca
  2. Abbott
  3. Bristol-Myers Squibb
  4. GlaxoSmithKline
  5. Eli Lilly
  6. Janssen
  7. National Institute of Mental Health
  8. National Institute of Drug Abuse
  9. Pfizer
  10. UCB Pharma
  11. Cephalon
  12. Forest
  13. Jazz
  14. Marriott Foundation
  15. Orexigen
  16. Shire
  17. Takeda
  18. Johnson & Johnson Pharmaceutical Research Development
  19. Bial
  20. Janssen-Cilag
  21. Organon
  22. Sanofi-Aventis
  23. Servier
  24. United BioSource Corporation
  25. UCB Belgium
  26. The Netherlands Organization for Health Research and Development
  27. European Union
  28. The Stanley Medical Research Institute
  29. Wyeth
  30. Chevy Chase, Maryland

Ask authors/readers for more resources

Objective: We examined the influence of age at onset of illness and the delay in time to first treatment on morbidity in adulthood. Method: 529 adult outpatients with a mean age of 42 years, who entered our research network from 1996 through 2001 and who were diagnosed with bipolar disorder according to DSM-IV criteria, were rated prospectively on a daily basis with the National Institute of Mental Health-Life Chart Method during naturalistic treatment for up to 4 years Results: Fifty percent of patients had illness onset in childhood (< 13 years of age) or adolescence (13-18 years of age) In year 1 of follow-up, these patients, compared to those with adult onset, showed significantly (P < .05) greater severity of depression and mania, greater number of episodes, more days depressed, more days of ultradian cycling, and fewer days euthymic After 4 years, the mean severity and duration of depression remained greater and the number of days euthymic fewer in those with childhood compared to adult onset (P < .05) The delays to first treatment correlated inversely with age at onset of illness. Independently, delay to first treatment was associated with more time depressed, greater severity of depression, greater number of episodes, more days of ultradian cycling, and fewer days euthymic (all P < .05) Conclusions: These data converge with other evidence that onset of bipolar disorder in childhood is common and often associated with extraordinarily long delays to first pharmacologic treatment Both childhood onset and treatment delay were associated with a persistently more adverse course of illness rated prospectively in adults These data should help foster efforts to ensure earlier and more effective treatment of bipolar illness in children and adolescents It is hoped that appropriate early intervention would result in a more benign illness and a better prognosis in adulthood J Clin Psychiatry 2010,71(7) 864-872 (C) Copyright 2010 Physicians Postgraduate Press, Inc

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available